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Biometrics, September 1987 to provide P-values for subsidiary endpoints. Thus, selection of a single primary endpoint is only a partial solution to the multiple-endpoints problem, and it may be wise to prespecify more stringent Type I error rates for secondary endpoints. This paper considers how to control P-values when all endpoints are analyzed on equal terms. For several normally distributed endpoints, one standard approach is Hotelling's T2 (Press, 1972) . However, as pointed out by O'Brien (1984) and Meier (1975) , Hotelling's T2 is intended to detect any departure from the null hypothesis and hence lacks power to detect any specific types of departure that are considered a priori to be biologically plausible. Thus, Hotelling's T2 is quite unsuitable for analysis of clinical trials and is not considered further.
For k endpoints without prespecified priorities, how can significance testing be used while (i) preserving a small overall Type I error rate and (ii) allowing for correlated endpoints? Section 2 considers the conservatism of Bonferroni correction for P-values while Section 3 explores a global test statistic for any set of asymptotically normal test statistics, with particular reference to a method proposed by O'Brien (1984). Section 4 presents two examples and Section 5 discusses the relative merits of the alternative approaches.
Bonferroni Correction
The Bonferroni inequality can be used to obtain an adjustment to the smallest P-value for significance tests on k endpoints (Miller, 1981; Armitage and Parmar, 1986) . If the k endpoints are independent then Pr(smallest P-value < a) = 1 -(1 -a)k a ak if a is small. Hence, Bonferroni correction has each P-value multiplied by k, the number of endpoints. That is, for an overall Type I error rate a, one accepts as statistically significant only those P-values less than a/k. In practice, endpoints are correlated, so that Bonferroni correction becomes conservative and Worsley (1982) has proposed one possible improvement. However, does such overcorrection seriously affect the power of a trial to detect genuine treatment differences?
It is difficult to obtain general results for nonnormal data or arbitrary correlations between endpoints. Therefore, we consider k normally distributed endpoints, each with known variance, for which all possible pairs have the same (known) correlation p within each of two treatment groups. Then, for any prespecified a, k, and p one can derive numerically that "nominal" value a' which the smallest of k one-sided P-values obtained from the normal test statistics will reach with probability a under the null hypothesis. Table 1 shows values of a' and its corresponding standardized normal deviate z' for k = 2, . .., 10 endpoints; for p = 0, .1, .3, .5, .7, .9; and for a = .05, .025. Values of z' were obtained using a quintic interpolation of tabular values for the probability distribution of the maximum of k equicorrelated standardized normal deviates published by Gupta (1963) . Table 1 also shows the exact values of a' for p = 0, which are slightly smaller than a/k.
For each number of endpoints k, a' increases as the correlation between endpoints increases, i.e., the conservatism of Bonferroni increases as p increases. However, the degree of conservatism is small for p < .5. For instance, with k = 5 endpoints, a = .05, and p = .5, a ' = .0128, compared with a/k = .01. Thus, Bonferroni correction works reasonably well for moderately correlated variables. Also, there is no noticeable deterioration in Bonferroni correction as the number of correlated endpoints increases. For two-sided testing, approximate results are obtained by doubling every one-sided probability (both for a and a') in Table 1 . Thus, for two-sided a = .05 one can use one-sided a = .025. The results are very slightly conservative, since the probability of any two variables exceeding the critical ay' levels in opposite directions is ignored, but this is negligibly small.
In reality, multiple endpoints are not usually equicorrelated and normally distributed. However, it seems plausible that similar findings would occur for any continuous The main drawback to Bonferroni correction is that it confines attention to the smallest P-value of k test statistics. Thus, five endpoints with P-values of .01, .7, .7, .7, .7 are considered more highly significant than five endpoints all at P = .02, whereas the latter appears to contain more convincing evidence of a treatment difference.
Thus, Bonferroni correction has its greatest power for alternative hypotheses in which only one of k endpoints has a nonzero treatment difference and, furthermore, one does not know in advance which endpoint that will be-a situation unlikely to arise in practice. For alternative hypotheses in which several variables depart from zero treatment difference in the same direction, Bonferroni correction will seriously lack power. However, since it is simple to apply, only slightly conservative, and easily understood, Bonferroni correction is still useful where the situation does not warrant more complex procedures.
A Global Test Statistic
Consider a randomized clinical trial with two treatment groups and k correlated endpoints. Later in this section we study the general problem of k endpoints with asymptotically normal test statistics, including binary data and survival data, but we begin with the multivariate normal case.
Often The m independent endpoints have larger weights than the (k -m) equicorrelated endpoints. However, the sum of these (k -m) correlated z-values will have greater weight than any single uncorrelated z-value.
Adaptation to Any Asymptotically Normal Test Statistics
Extension of the above global test statistic to any set of asymptotically normal test statistics whose correlation matrix can be estimated is now illustrated for several types of data.
(i) Normal endpoints with unknown variance-covariance matrix which is the same for both treatment groups O'Brien (1984) proposed replacing 2 by the usual pooled withintreatment estimate S. z is then replaced by the k two-sample t-statistics t and formula (1) becomes
This has an asymptotic standardized normal distribution, but does not follow a t distribution. We have undertaken some simulation studies to supplement those already reported by O'Brien (1984). Briefly, for k = 2 endpoints a t distribution on N -4 degrees of freedom appears a good approximation even for N quite small (e.g., N = 10). However, for k = 5 endpoints, convergence to a standardized normal distribution is slower. For instance, the 5% point of formula (2) for any i $ j, where sij is the proportion of all patients with responses for both variables i and j. Then, substituting (5) for Xij in 2 and using formula (1) provides an asymptotically normal global test statistic. Further research is needed to assess this approximation for small samples, though it seems reasonable to suppose that if the sample sizes are adequate for each univariate normal approximation zi, then the global test should also be an adequate approximation. Also, the use of a continuity correction for each zi may be inappropriate, since the corrected global test would then be conservative, a common problem for attempts at continuity correction for combinations of discrete asymptotically normal test statistics. Estimates of Zij can also be obtained for mixtures of binary and normal endpoints.
(vi) Survival data using log-rank tests Suppose endpoint j is a censored variable-say, patient survival times. Then the normal approximation to the log-rank test is given by where Rd is the total number of patients who both responded and died, p(u) is the proportion of patients who responded among those at risk at time u, and the summation is over all death times tj. To obtain an anticipated positive correlation, one can consider the proportion of patients failing to respond.
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For this survival problem, the asymptotic normality of formula (1) can be utilized. Further adaptations are envisaged for other combinations of asymptotically normal test statistics, e.g., two log-rank statistics, normal and log-rank, two-sample Wilcoxon tests, and other linear rank statistics. For two log-rank statistics the correlation estimate of Wei and Lachin (1984) may be used.
In principle, there is no difficulty in estimating correlations, leading to an asymptotically valid use of formula (1). This general strategy for using a global test statistic is now illustrated by two examples.
Examples
Example 1: A Crossover Trial of Chronic Respiratory Disease Seventeen patients with asthma or chronic obstructive airways disease entered a randomized, double-blind crossover trial of an inhaled active drug versus placebo. Each patient received active drug and placebo for consecutive 4-week periods in a random order. The main purpose was to study the drug's possibly harmful effect on lung mucociliary clearance, and analysis of those results produced no evidence of harm. In addition, standard respiratory function measures were taken at the end of both treatment periods. These were peak expiratory flow rate (PEFR), forced expiratory volume (FEV1), and forced vital capacity (FVC), the latter two being expressed as a percentage of the predicted value for that patient's age, sex, and height in the normal population. In this trial the drug or placebo was given in addition to each patient's normal treatment for respiratory disease. A secondary question was whether the addition of this extra inhaled drug could further improve respiratory function.
For each measure there were no signs of period or carryover effects, so that the univariate analysis of drug versus placebo was performed using paired t-tests as follows: 
Discussion
Inevitably, there is no unique, optimal strategy for the use of significance testing when analyzing multiple endpoints in clinical trials. This paper has explored two quite different options, the use of Bonferroni correction and various extensions of a global test statistic proposed by O'Brien (1984). The main advantage of Bonferroni correction is its simplicity, and its slight conservatism is unlikely to be a serious problem. Thus, Bonferroni correction remains useful for avoiding overinterpretation of a set of univariate P-values for multiple endpoints. However, since Bonferroni correction utilizes only the most extreme of k P-values, it fails to make efficient use of the collective data, particularly in circumstances where one expects several endpoints to behave similarly. One possible alternative is to modify the Bonferroni procedure to take account of more than one P-value, as considered by Simes (1986) .
The main value of the global test statistic (1) is its applicability to any set of asymptotically normal test statistics, as explored in Section 3. Multivariate methods have often been confined to quantitative data, whereas clinical trials frequently generate binary and censored data. Estimating the correlation matrix X: for asymptotically normal test statistics obtained from such nonnormal data was illustrated by formulae (5) and (7). Another issue is the robustness of the asymptotically normal statistic for finite sample sizes, and this depends primarily on the validity of each univariate normal approximation. O'Brien (1984) has previously reported encouraging findings for quantitative data but we intend to undertake further simulation studies, e.g., for binary and survival data, to explore this issue.
Formula (1) assumes all endpoints are equally important, i.e., the approach is optimal for alternative hypotheses of equal (standardized) magnitude for all endpoints. However, one simple method of attaching unequal priorities (weights) to the various endpoints is as follows. Consider an alternative hypothesis in which k endpoints have standardized treatment differences g/wi, ... , g/wk. Then the optimal test replaces formula ( where W is a diagonal weighting matrix with elements w1, ... ., Wk. Both the relative clinical importance of the endpoints and their relative statistical power to detect realistic treatment differences could also play a role in determining such weights. However, one should specify any unequal weights beforehand in order to avoid subjectivity.
Even with endpoints of equal priority, the generalized least squares principle produces a test statistic that is a weighted mean of k standardized normal deviates. Thus, endpoints that are more highly correlated with one another make smaller individual contributions. O'Brien (1984) also considered an alternative procedure based on ordinary least squares that uses the unweighted mean of k standardized normal deviates. That is, formula (1) is replaced by kf/(J '-XJ)112, which is also a standardized normal deviate under the global null hypothesis. With only two endpoints, the two procedures are identical. For k > 2 endpoints, equal correlations among the endpoints are unlikely and therefore the weighted statistic should be more powerful.
However, for certain correlation matrices it is possible for the weighted statistic (1) to have negative weights, which seems untenable from a practical viewpoint. In our experience this appears likely to arise when one is attempting to combine data from diverse endpoints which have an irregular correlation structure. For instance, the crossover trial described in Example 1 had an additional and less widely-used variable, the penetration index (PI), which measures the ability of a deep inhalation to reach small airways. Expanding the analysis to four variables led to the following estimated correlation matrix S derived from patient paired differences: combines tumour response (a short-term measure of drug activity) and patient survival (a more "patient-oriented" assessment of overall benefit). However, since a tumour response usually enhances survival, such a combination may have some merit.
The analysis strategy for multiple endpoints should affect the design. First, awareness of the difficulties in interpreting multiple endpoints should help to avoid an unnecessary excess of endpoints. A clear statement in the trial protocol of the priorities among endpoints, including the possible selection of a single primary endpoint, is desirable. Indeed, the main value of a global test statistic may be in analyzing secondary endpoints, leaving the primary endpoint for univariate analysis. It may sometimes be useful to redefine certain sets of endpoints that assess specific aspects of patient response, each set requiring a separate collective analysis. Also, the method of analysis, Bonferroni correction or a global test statistic, should be specified in the study protocol to avoid any post hoc selection.
In the presentation of results, a global test statistic could either replace or complement the univariate analysis of each endpoint. In order to preserve effective communication with nonstatisticians, the latter approach may be preferable. However, a nonsignificant global test would clearly inhibit any claims of treatment difference for individual endpoints. This paper has concentrated on significance testing for multiple endpoints, but estimation methods should also be considered. By a procedure analogous to Bonferroni correction, one could widen each univariate confidence interval but this may be unnecessary since uncorrected confidence intervals are usually sufficiently wide to deter exaggerated claims of treatment difference.
Methods for defining multivariate confidence intervals, as in Miller (1981) , are difficult to present visually except for the bivariate case. One possibility is to obtain a single confidence interval of treatment difference from the generalized least squares estimation in formula (1). This assumes that the true standardized difference is the same for all endpoints, so this approach may be too abstract for general use.
Other problems worth exploring include the use of multiple endpoints in interim analyses, the extension to more than two treatments as discussed by O'Brien (1984), adjustment for prognostic factors, and methods of assessing the required size of trials with multiple endpoints. Thus, further research is needed to better integrate the concept of a global test statistic into the clinical trial statistician's repertoire, with emphasis placed on the feasibility of implementing such methods in actual trials. RESUME Les comparaisons de traitements dans les essais cliniques randomises mettent, en general, en jeu plusieurs criteres finaux, de telle sorte que les tests de signification conventionnels peuvent augmenter serieusement 1'erreur totale de Type I. Une option possible est de selectionner un seul critere primaire pour faire une inference statistique correcte, mais ce n'est pas toujours possible. Une autre approche est de faire la correction de Bonferroni (c'est-a-dire multiplier chaque P-valeur par le nombre total de criteres). Son conservatisme pour des criteres correles est etudie pour des donnees suivant une loi normale multidimensionnelle. Une troisieme approche consiste a trouver un test statistique global approprie, et cet article etudie un tel test, applicable a tout ensemble de statistiques de tests asymptotiquement distributes suivant une loi normale. Avec cette demarche generate, on peut aussi bien considerer des criteres quantitatifs, binaires ou de survie. L'article presente aussi deux exemples, et discute les merites respectifs des differentes strategies proposees. . In what follows all the arguments will be made under the null hypothesis of no treatment effect on response or survival. We shall also condition on the Z's; however, we will assume that as N grows the proportion of treatment A will converge to a constant /i.
The proportions test, given by (4), can also be written as a normalized sum of independent mean zero random variables. If we denote by T. 
